share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4：持股變動聲明-股東 Cormorant Asset Management, LP
美股SEC公告 ·  04/23 04:02
牛牛AI助理已提取核心訊息
Cormorant Asset Management, LP has completed a significant acquisition of shares in EyePoint Pharmaceuticals, Inc. (EYPT). On April 18, 2024, the asset management firm purchased a total of 581,765 shares of common stock in two separate transactions. The first transaction involved the purchase of 395,244 shares at a price of $17.62 per share, while the second transaction saw the acquisition of 186,521 shares at $18.90 each. Following these transactions, Cormorant Asset Management's total beneficial ownership in EyePoint Pharmaceuticals has risen to 7,475,000 shares. The transactions were executed on the open market and are part of the firm's investment strategy.
Cormorant Asset Management, LP has completed a significant acquisition of shares in EyePoint Pharmaceuticals, Inc. (EYPT). On April 18, 2024, the asset management firm purchased a total of 581,765 shares of common stock in two separate transactions. The first transaction involved the purchase of 395,244 shares at a price of $17.62 per share, while the second transaction saw the acquisition of 186,521 shares at $18.90 each. Following these transactions, Cormorant Asset Management's total beneficial ownership in EyePoint Pharmaceuticals has risen to 7,475,000 shares. The transactions were executed on the open market and are part of the firm's investment strategy.
Cormorant Asset Management, LP已完成對EyePoint製藥公司（埃及）股份的重大收購。2024年4月18日，這家資產管理公司通過兩筆單獨的交易共購買了581,765股普通股。第一筆交易涉及以每股17.62美元的價格購買395,244股股票，而第二筆交易以每股18.90美元的價格收購了186,521股股票。這些交易之後，Cormorant Asset Management在EyePoint Pharmicals的總實益所有權已增至7,475,000股。這些交易是在公開市場上執行的，是公司投資策略的一部分。
Cormorant Asset Management, LP已完成對EyePoint製藥公司（埃及）股份的重大收購。2024年4月18日，這家資產管理公司通過兩筆單獨的交易共購買了581,765股普通股。第一筆交易涉及以每股17.62美元的價格購買395,244股股票，而第二筆交易以每股18.90美元的價格收購了186,521股股票。這些交易之後，Cormorant Asset Management在EyePoint Pharmicals的總實益所有權已增至7,475,000股。這些交易是在公開市場上執行的，是公司投資策略的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。